Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06401577 · ClinicalTrials.gov registry record

Diabetes RElated to Acute Pancreatitis and Its Mechanisms: Metabolic Outcomes Using Novel CGM Metrics

A clinical trial of Acute Pancreatitis, sponsored by Milton S. Hershey Medical Center.

Recruiting
Registry status
800
Enrollment target
13
Study locations

NCT06401577 is a study of Acute Pancreatitis that is actively recruiting participants, run by Milton S. Hershey Medical Center. The registered enrollment target is 800 participants, below the 2,239-participant average among 10 other Acute Pancreatitis trials with a reported enrollment target (64% lower). The trial reports 13 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06401577, a study of Acute Pancreatitis, is actively recruiting participants, sponsored by Milton S. Hershey Medical Center.

RECRUITING
Registry status
800 participants
Enrollment target
13
Study locations

Study Summary

The DREAM-ON study will investigate whether continuous glucose monitoring (CGM) is useful to predict risk for developing diabetes mellitus (DM) and pre-diabetes mellitus (PDM), the need for insulin therapy among those who develop DM, and to determine whether CGM can provide insight into the pathophysiology and DM subtype among participants who have experienced an episode of acute pancreatitis (AP). Thus, the results of the DREAM-ON study could inform future clinical practice guidelines for the management AP as well as potentially extending the licensing authorization for CGM to include use in patients with pancreatogenic (Type 3c) DM.

Conditions Studied

Acute Pancreatitis

Interventions

  • DEVICE Dexcom Continuous Glucose Monitor (CGM)

Study Locations (13)

California

  • University of Southern California - Los Angeles
  • Cedars-Sinai Medical Center - Los Angeles
  • Stanford University - Stanford

Florida

  • University of Florida - Gainesville
  • AdventHealth - Orlando

Illinois

  • Northwestern University - Chicago
  • University of Illinois at Chicago - Chicago

Indiana

  • Indiana University - Indianapolis

Maryland

  • Johns Hopkins University - Baltimore

Minnesota

  • University of Minnesota - Minneapolis

Ohio

  • Ohio State University - Columbus

Pennsylvania

  • University of Pittsburgh - Pittsburgh

Trial Details

FieldValue
Enrollment Target 800 participants
Start Date 2024-10-16
Est. Completion 2027-03-31

Sponsor

Milton S. Hershey Medical Center

396 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06401577

The ClinicalTrials.gov registry entry for NCT06401577 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 800 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,239-participant average among 10 other Acute Pancreatitis trials with a reported enrollment target (64% lower). The listed sponsor is Milton S. Hershey Medical Center, which has 396 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Acute Pancreatitis appearing as the primary indexed condition, and to 1 intervention - of which Dexcom Continuous Glucose Monitor (CGM) is the first listed.

NCT06401577 reports 13 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, Illinois.

Frequently Asked Questions

What is clinical trial NCT06401577 about?

NCT06401577 is a clinical study titled "Diabetes RElated to Acute Pancreatitis and Its Mechanisms: Metabolic Outcomes Using Novel CGM Metrics". The DREAM-ON study will investigate whether continuous glucose monitoring (CGM) is useful to predict risk for developing diabetes mellitus (DM) and pre-diabetes mellitus (PDM), the need for insulin therapy among those who develop DM, and to determine whether CGM can provide insight into the pathophy...

What is the current status of trial NCT06401577?

This trial is currently recruiting. The enrollment target is 800 participants. The study started on 2024-10-16. Estimated completion is 2027-03-31.

What conditions does trial NCT06401577 study?

This clinical trial studies the following conditions: Acute Pancreatitis.

What interventions are being tested in trial NCT06401577?

The interventions under investigation include: Dexcom Continuous Glucose Monitor (CGM) (DEVICE).

Who is sponsoring clinical trial NCT06401577?

This trial is sponsored by Milton S. Hershey Medical Center, which has 396 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06401577 being conducted?

This trial has 13 study locations across California, Florida, Illinois, Indiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Pancreatitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Acute Pancreatitis

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.